2017
PTEN loss as a predictive biomarker in head and neck squamous cell cancer (HNSCC) patients treated with cetuximab (C).
Eze N, Chung C, Neumeister V, Sandoval-Schaefer T, Lee J, Burtness B. PTEN loss as a predictive biomarker in head and neck squamous cell cancer (HNSCC) patients treated with cetuximab (C). Journal Of Clinical Oncology 2017, 35: e17520-e17520. DOI: 10.1200/jco.2017.35.15_suppl.e17520.Peer-Reviewed Original ResearchM HNSCCHazard ratioPTEN lossPTEN analysisLow tumorsExact testHigh tumorNeck squamous cell cancer patientsSquamous cell cancer patientsCox proportional hazards modelWild-type patientsHigh expression groupProportional hazards modelFisher's exact testPTEN testingC therapyFirst tertilePatient selectionKaplan-MeierType patientsCancer patientsPredictive biomarkersPIK3CA mutationsExpression groupHazards model
2010
The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss.
Fountzilas G, Pectasides E, Kountourakis P, Gouveris P, Sasaki C, Duffey D, Pectasides D, Rimm D, Burtness B, Psyrri D. The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss. Journal Of Clinical Oncology 2010, 28: 5550-5550. DOI: 10.1200/jco.2010.28.15_suppl.5550.Peer-Reviewed Original Research